OCGN Ocugen, Inc.
USHealthcareAs of 2026-07-10 16:00
Why OCGN matters now
Ocugen, Inc. (OCGN) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.47 with -0.00% on the session and $497.6M in market capitalization; recent performance reads 1-month -4.62% and YTD -8.15%.
The latest financial table shown here is Q1 2026, with revenue of $1.5M, net income of $-19.2M, and EPS of $-0.06. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -14.2%.
The latest indexable market news headline is "Ocugen to Participate in Upcoming July Industry Conferences" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $5.00; recent insider activity includes Johnson-Greene Treerita Essalima filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
68.45
P/S
94.01
EV/EBITDA
-6.56
DCF Value
$-0.20
FCF Yield
-14.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-1483.9%
Net Margin
-1605.2%
ROE
-127987.5%
ROA
-126.0%
ROIC
-157.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.5M | $-19.2M | $-0.06 |
| Q4 2025 | $-193.0K | $-17.7M | $-0.06 |
| FY 2025 | $4.4M | $-67.8M | $-0.23 |
| Q3 2025 | $1.8M | $-20.1M | $-0.07 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$5.00
Target (Median)
$5.00
Target Range
$3.50 - $6.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.21
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.